先瑞達醫療-B(06669.HK)公佈年度業績，研發成本增加69.2%至1.41億元
格隆匯3月30日丨先瑞達醫療-B(06669.HK)發佈年度業績公吿，2021年實現收益人民幣3.038億元，同比增長56.6%；毛利人民幣2.659億元，同比增長62.4%；年內經調整溢利淨額人民幣4239萬元，同比增長141.8%。集團該年度的研發成本約為人民幣1.413億元，較2020年增加約69.2%。該增加主要由於於2020年5月27日收購的深圳研發中心的研發開支併入集團自收購日期起至2021年度的綜合財務報表；員工成本增加；2021年的員工持股計劃開支；及加大投入正在進行的研發項目。
2021年，集團在研發範疇方面取得重大進展。2021年度，五款產品已送往型式檢驗、七款產品正進行臨牀試驗、兩款產品已完成臨牀試驗、兩款產品已向國家藥監局遞交申請及兩款產品已獲批准(包括AcoArt Orchid® & Dhalia™ 一款升級產品)。集團亦已於該年度註冊十項額外專利。管線研發順利進行的同時，集團的入院工作亦同步推進。截至2021年12月31日，集團的BTK DCB(膝下藥物球囊)實現288家醫院入院，同時完成於27個省份及自治區掛網。集團的ATK DCB(膝上藥物球囊)實現1283家醫院入院。集團於2021年11月上市的外周抽吸導管已完成於國家採購平台掛網。產研的穩定利好狀態直接導致年度收益快速增長。2021年度，集團的收益達約人民幣3.038億元，同比增加約56.6%。集團的核心產品AcoArt Orchid®& Dhalia™及AcoArt Tulip™ & Litos™成為集團收益的核心來源。
2021年，集團對動脈鈣化市場、靜脈市場以及血管瘤市場進行了深入調查與研討，集團開始在該等領域着手佈局。截至2021年12月31日，集團已經開發包括外周IVL系統(血管外科)、外周彈簧圈(血管外科)及冠狀IVL系統(心臟科)等在內的六款全新產品，且產品開發進展速度極快。集團認為，這一切成績歸功於兩點。其一，其歸功於集團對市場潛力的洞察力、判斷力與前瞻性。基於紮根行業數十年的經驗幫助集團做出更好的決策與判斷，進一步開發該等潛力領域市場。其二，其歸功於集團一流的執行力。集團的外周IVL系統從開展項目到落實IVL系統的設計僅用了7個月時間。除此之外，集團其餘產品線正按照原計劃如期推進。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
